- Conditions
- Healthy Male Volunteer
- Interventions
- JNJ-38518168 (30 mg), JNJ-38518168 (10 mg), JNJ-38518168 (3 mg), Placebo, Midazolam and JNJ-38518168
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 94 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Cypress, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 868
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- NNC0385-0434 A 15 mg, NNC0385-0434 A 40 mg, Placebo I A (for NNC0385-0434 A 15 mg), NNC0385-0434 A 100 mg, Placebo I A (for NNC0385-0434 A 40 mg), Placebo II A (for NNC0385-0434 A 100 mg), Evolocumab 140 mg/mL, Repatha®
- Drug · Other
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 13
- States / cities
- Palm Springs, California • Boca Raton, Florida • Fort Lauderdale, Florida + 9 more
- Conditions
- Metastatic Cancer, Prostate Cancer
- Interventions
- zoledronic acid, placebo, androgen deprivation therapy, GnRH agonist, Calcium supplement, Vitamin D
- Drug · Other · Dietary Supplement
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 645 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2014
- U.S. locations
- 238
- States / cities
- Mobile, Alabama • Fort Smith, Arkansas • Little Rock, Arkansas + 159 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- AZD1656, Digoxin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Restless Legs Syndrome
- Interventions
- aplindore MR tablets or Placebo
- Drug
- Lead sponsor
- Neurogen Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Tuscon, Arizona • Oceanside, California + 19 more
- Conditions
- Nocturia, Daytime Sleepiness
- Interventions
- Armodafinil, Placebo
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Obesity, Overweight, Type 2 Diabetes
- Interventions
- Orforglipron, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 35
- States / cities
- Sun City West, Arizona • Tucson, Arizona • San Ramon, California + 31 more
- Conditions
- Opioid Use Disorder
- Interventions
- ASP8082, morphine, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Heart Failure With Reduced Ejection Fraction (HFrEF)
- Interventions
- CRD-4730, Placebo
- Drug
- Lead sponsor
- Cardurion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 525 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Pasadena, California • Bloomfield Hills, Michigan
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Placebo, ECC5004
- Drug
- Lead sponsor
- Eccogene
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- Carcinoid Tumor, Malignant Carcinoid Syndrome
- Interventions
- Octreotide, Placebo, Everolimus
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 429 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 38
- States / cities
- Tucson, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 32 more
- Conditions
- Symptomatic Menopause, Cognitive Impairments
- Interventions
- Lisdexamfetamine, Placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 45 Years to 60 Years · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hypertension, Portal
- Interventions
- Avenciguat (BI 685509), Placebo matching Avenciguat (BI 685509)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 6
- States / cities
- Pasadena, California • Rialto, California • Miami Lakes, Florida + 3 more
- Conditions
- Postherpetic Neuralgia, Pain
- Interventions
- V116517 50-mg tablets, V116517 30-mg tablets, Pregabalin capsules, Placebo
- Drug
- Lead sponsor
- Purdue Pharma LP
- Industry
- Eligibility
- 21 Years to 90 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 28
- States / cities
- Tucson, Arizona • La Jolla, California • North Hollywood, California + 25 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- ADZENYS XR-ODT, Placebo Oral Tablet
- Drug
- Lead sponsor
- Aytu BioPharma, Inc.
- Industry
- Eligibility
- 4 Years to 5 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Palmar Hyperhidrosis
- Interventions
- Dexmecamylamine HCl, Placebo
- Drug · Other
- Lead sponsor
- Atacama Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 3
- States / cities
- San Diego, California • St Louis, Missouri • Norfolk, Virginia
- Conditions
- Major Depressive Disorder
- Interventions
- Dose-matched placebo, Vilazodone
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 518 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 14
- States / cities
- Beverly Hills, California • Encino, California • New Port Beach, California + 11 more
- Conditions
- Methamphetamine Dependence, Substance Abuse, Methamphetamine Abuse
- Interventions
- Varenicline, Placebo
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Healthy Volunteers
- Interventions
- ACP-196, Moxifloxacin 400 mg, Placebo
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Upadacitinib, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,328 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 87
- States / cities
- Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 73 more
- Conditions
- Hypertension
- Interventions
- Aliskiren, Valsartan, Placebo for Aliskiren, Placebo for Valsartan
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 4
- States / cities
- Newark, Delaware • Kansas City, Missouri • Camden, New Jersey + 1 more
- Conditions
- Male Osteoporosis
- Interventions
- Teriparatide or human parathyroid hormone (PTH) 1-34, Cinacalcet, placebo tablet, Calcium citrate tablet, Vitamin D3
- Drug · Dietary Supplement
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 60 Years to 85 Years · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- Obeticholic Acid, Atorvastatin, Placebo
- Drug
- Lead sponsor
- Intercept Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • La Jolla, California • Rialto, California + 19 more
- Conditions
- Pervasive Development Disorders
- Interventions
- placebo, extended-release guanfacine
- Other · Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 5 Years to 14 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 5
- States / cities
- Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 2 more